News | May 10, 2011

Nuclear Imaging Advocates Visit Capitol Hill

May 10, 2011 – Thirty Society of Nuclear Medicine (SNM) members visited Capitol Hill on ar IMay 2 to meet with congressional offices on a variety of issues facing the nuclear medicine and molecular imaging community. Forty-eight meetings were held with staff members from key congressional committees and from the local districts of the SNM members.

"Going to Capitol Hill has a profound impact on how members of Congress view the issues," said Robert Atcher, MBA, Ph.D., chair of SNM's Commission on Government Affairs. "According to the Congressional Management Foundation, a visit from a local constituent has a 99 percent rating for ability to influence a member of Congress who has not already arrived at a firm decision on an issue. That's what we hoped to accomplish in our visits to the Hill this week." He continued, "We also encourage everyone who participated, as well as those who could not, to contact their representatives' and senators' offices in their districts or state to reinforce the message regarding the value of nuclear medicine."

In their meetings with congressional staff members, SNM members shared background information on nuclear medicine and molecular imaging. Explaining that most people have a friend or family member who has benefited from nuclear and molecular imaging procedures, they also presented an overview of SNM and the work of the society.

After setting the stage, SNM advocates focused on four specific issues facing the field. Members of Congress were asked to support $15.4 million in funding for nuclear medicine research in the fiscal year (FY) 2011 Department of Energy (DOE) Budget and the FY 2012 Energy and Water Appropriations bill. In addition, they were asked to support the Comprehensive AIDS Resources Emergency (CARE) Act and the American Medical Isotopes Production Act of 2011, as well as to ensure adequate and appropriate reimbursement for radiopharmaceuticals.

"As a first-time advocate, going up to Capitol Hill and being a part of the political process was a really wonderful experience. Having made a connection with the office of my local congressional representative, I plan to stay in touch and continue to advocate for nuclear medicine and molecular imaging," said Michelle Falance, CNMT, a technologist at the University of Pennsylvania Hospital.

SNM members unable to attend the society's Capitol Hill Day can still make a difference. "We are always looking to grow our network of grassroots support; a letter or a phone call from a constituent can go a long way in the political process," said Sue Bunning, SNM director of health policy and regulatory affairs. Those looking to get involved should e-mail [email protected] for more information.

For more information: www.snm.org

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init